In vitro cardiovascular safety profile of BKI-1708.
收藏NIAID Data Ecosystem2026-05-02 收录
数据链接：
官方服务：
资源简介：
In vitro cardiovascular safety profile of BKI-1708.
应用场景：
创建时间：
2025-07-30
相关数据集
Adverse drug events associated with metreleptin administration: a real-world pharmacovigilance study from 2014 to 2024 using the FAERS database
This study analyzed adverse drug event (ADE) signals associated with metreleptin using the FDA Adverse Event Reporting System (FAERS) to provide insights for safe clinical use. Data from 1 January 201
DataCite Commons2026-05-04 更新120
Rates of systemic adverse effects of head-to-head studies (direct comparison).
Nr: Not reported. *Data from CATT appendix: they refer to duodenal ulcer haemorrhage, gastric ulcer haemorrhage, (lower) gastrointestinal haemorrhage, rectal haemorrhage. #Rates refer mainly to pneumo
NIAID Data Ecosystem60
Efficacy, safety, and ARIA risk of anti–β-amyloid antibodies in early Alzheimer’s disease: a systematic review, meta-analysis, and meta-regression
Alzheimer’s disease (AD) is the most prevalent cause of dementia and has been closely linked to βSupplemental data for this article can be accessed online at ht tps://doi.org/-amyloid accumulation. Ho
NIAID Data Ecosystem40
A Phase 2 Randomized Trial of Apremilast in Patients With Atopic Dermatitis. A Phase 2 Randomized Trial of Apremilast in Patients With Atopic Dermatitis
A phase 2, double-blind, placebo-controlled trial evaluated apremilast efficacy, safety, and pharmacodynamics in adults with moderate to severe atopic dermatitis (AD). Overall design: Patients were ra
NIAID Data Ecosystem100
Prior and Concomitant Medications and Systemic Antimicrobials in Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants <750 Grams Birth Weight
Prior and Concomitant Medications and Systemic Antimicrobials Dataset Study Description This was a prospective, randomized, double-blind, multi-center, efficacy study comparing fluconazole prophylaxis
NIAID Data Ecosystem50
